Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25-26 August 2005, London, UK

Vaccine

Volumn 24, Issue 49-50, 2006, Pages 7056-7065

  Roberts, Anjeanette ^a   Wood, John ^b   Subbarao, Kanta ^a   Ferguson, Morag ^b   Wood, David ^c   Cherian, Thomas ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Animal models; Guidelines; SARS virus; Vaccines

Indexed keywords

ANTIGEN; ANTIVIRUS AGENT; PROTEIN S; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE;

ARTICLE; BIOSAFETY; CHINA; CORONAVIRUS; DRUG EFFICACY; EPIDEMIC; FATALITY; FOOD AND DRUG ADMINISTRATION; IMMUNE RESPONSE; IMMUNOASSAY; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; UNITED KINGDOM; UNITED STATES; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; ARVICOLINAE; CRICETINAE; DISEASE MODELS, ANIMAL; FERRETS; GUINEA PIGS; MICE; PRIMATES; RATS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL VACCINES; VIVERRIDAE;

EID: 33846242183     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.07.009     Document Type: Article

References (85)

1. Peiris J.S., Guan Y., and Yuen K.Y. Severe acute respiratory syndrome. Nat Med 10 Suppl. 12 (2004) S88-S97
2. Parry J. WHO investigates China's fall in SARS cases. BMJ 326 7402 (2003) 1285
3. Fleck F. WHO says SARS outbreak is over, but fight should go on. BMJ 327 7406 (2003) 70
4. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. http://www.who.int/csr/sars/country/table2003_09_23/en/index.html.
5. Drosten C., Gunther S., Preiser W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348 20 (2003) 1967-1976
6. Peiris J.S., Lai S.T., Poon L.L., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 9366 (2003) 1319-1325
7. Rota P.A., Oberste M.S., Monroe S.S., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 5624 (2003) 1394-1399
8. Snijder E.J., Bredenbeek P.J., Dobbe J.C., et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 331 5 (2003) 991-1004
9. Marra M.A., Jones S.J., Astell C.R., et al. The Genome sequence of the SARS-associated coronavirus. Science 300 5624 (2003) 1399-1404
10. Holmes K.V. SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest 111 11 (2003) 1605-1609
11. Guan Y., Zheng B.J., He Y.Q., et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science 302 5643 (2003) 276-278
12. Poon L.L., Guan Y., Nicholls J.M., Yuen K.Y., and Peiris J.S. The aetiology, origins, and diagnosis of severe acute respiratory syndrome. Lancet Infect Dis 4 11 (2004) 663-671
13. Li F., Li W., Farzan M., and Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309 5742 (2005) 1864-1868
14. Holmes K.V. Structural biology. Adaptation of SARS coronavirus to humans. Science 309 5742 (2005) 1822-1823
15. Li W., Shi Z., Yu M., et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 310 5748 (2005) 676-679
16. Lau S.K., Woo P.C., Li K.S., et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 102 39 (2005) 14040-14045
17. Peiris J.S., Chu C.M., Cheng V.C., et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361 9371 (2003) 1767-1772
18. Booth C.M., Matukas L.M., Tomlinson G.A., et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 289 21 (2003) 2801-2809
19. Weiss S.R., and Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 69 4 (2005) 635-664
20. Zhu M. SARS immunity and vaccination. Cell Mol Immunol 1 3 (2004) 193-198
21. Subbarao K., McAuliffe J., Vogel L., et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol 78 7 (2004) 3572-3577
22. Roberts A., Paddock C., Vogel L., Butler E., Zaki S., and Subbarao K. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol 79 9 (2005) 5833-5838
23. Martina B.E., Haagmans B.L., Kuiken T., et al. Virology: SARS virus infection of cats and ferrets. Nature 425 6961 (2003) 915
24. Roberts A., Vogel L., Guarner J., et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol 79 1 (2005) 503-511
25. Fouchier R.A., Kuiken T., Schutten M., et al. Aetiology: Koch's postulates fulfilled for SARS virus. Nature 423 6937 (2003) 240
26. Kuiken T., Fouchier R.A., Schutten M., et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 362 9380 (2003) 263-270
27. Gao W., Tamin A., Soloff A., et al. Effects of a SARS-associated coronavirus vaccine in monkeys. Lancet 362 9399 (2003) 1895-1896
28. McAuliffe J., Vogel L., Roberts A., et al. Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology 330 1 (2004) 8-15
29. Rowe T., Gao G., Hogan R.J., et al. Macaque model for severe acute respiratory syndrome. J Virol 78 20 (2004) 11401-11404
30. Qin C., Wang J., Wei Q., et al. An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus. J Pathol 206 3 (2005) 251-259
31. Zhou T., Wang H., Luo D., et al. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies. J Virol 78 13 (2004) 7217-7226
32. Zhang H., Wang G., Li J., et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J Virol 78 13 (2004) 6938-6945
33. Buchholz U.J., Bukreyev A., Yang L., et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci USA 101 26 (2004) 9804-9809
34. Sui J., Li W., Roberts A., et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 79 10 (2005) 5900-5906
35. Berry J.D., Jones S., Drebot M.A., et al. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. J Virol Methods 120 1 (2004) 87-96
36. Bisht H., Roberts A., Vogel L., et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci USA 101 17 (2004) 6641-6646
37. Yang Z.Y., Kong W.P., Huang Y., et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428 6982 (2004) 561-564
38. Weingartl H., Czub M., Czub S., et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol 78 22 (2004) 12672-12676
39. Bukreyev A., Lamirande E.W., Buchholz U.J., et al. Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363 9427 (2004) 2122-2127
40. Liu R.Y., Wu L.Z., Huang B.J., et al. Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res 112 1-2 (2005) 24-31
41. Guillen J., Perez-Berna A.J., Moreno M.R., and Villalain J. Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism. J Virol 79 3 (2005) 1743-1752
42. Glass W.G., Subbarao K., Murphy B., and Murphy P.M. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol 173 6 (2004) 4030-4039
43. Chepurnov A.A., Dadaeva A.A., Malkova E.M., Kolesnikov S.I., and Sandakhchiev L.S. Symptoms of infection caused by SARS coronavirus in laboratory mice and guinea pigs. Dokl Biol Sci 397 (2004) 310-313
44. Wu D., Tu C., Xin C., et al. Civets are equally susceptible to experimental infection by two different severe acute respiratory syndrome coronavirus isolates. J Virol 79 4 (2005) 2620-2625
45. Gao H., Peng J.P., Deng W., et al. Infection of SARS-CoV on juvenile and adult Brandt's vole Microtus brandtii. Chin Sci Bull 50 12 (2005) 1199-1204
46. Sui J., Li W., Murakami A., et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 101 8 (2004) 2536-2541
47. Greenough T.C., Babcock G.J., Roberts A., et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis 191 4 (2005) 507-514
48. ter Meulen J., Bakker A.B., van den Brink E.N., et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 363 9427 (2004) 2139-2141
49. Traggiai E., Becker S., Subbarao K., et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med 10 8 (2004) 871-875
50. Roberts A., Thomas W.D., Guarner J., et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. J Infect Dis 193 5 (2006) 685-692
51. Faber M., Lamirande E.W., Roberts A., et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 86 Pt 5 (2005) 1435-1440
52. Kapadia S.U., Rose J.K., Lamirande E., Vogel L., Subbarao K., and Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 340 2 (2005) 174-182
53. Zakhartchouk A.N., Viswanathan S., Mahony J.B., Gauldie J., and Babiuk L.A. Severe acute respiratory syndrome coronavirus nucleocapsid protein expressed by an adenovirus vector is phosphorylated and immunogenic in mice. J Gen Virol 86 Pt 1 (2005) 211-215
54. Zeng F., Chow K.Y., Hon C.C., et al. Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem Biophys Res Commun 315 4 (2004) 1134-1139
55. Takasuka N., Fujii H., Takahashi Y., et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 16 10 (2004) 1423-1430
56. Tang L., Zhu Q., Qin E., et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol 23 6 (2004) 391-394
57. Xiong S., Wang Y.F., Zhang M.Y., et al. Immunogenicity of SARS inactivated vaccine in BALB/c mice. Immunol Lett 95 2 (2004) 139-143
58. Zakhartchouk A.N., Liu Q., Petric M., and Babiuk L.A. Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines. Vaccine 23 35 (2005) 4385-4391
59. Zhou J., Wang W., Zhong Q., et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine 23 24 (2005) 3202-3209
60. Spruth M., Kistner O., Savidis-Dacho H., et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24 5 (2006) 652-661
61. Tirado S.M., and Yoon K.J. Antibody-dependent enhancement of virus infection and disease. Viral Immunol 16 1 (2003) 69-86
62. Takada A., and Kawaoka Y. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev Med Virol 13 6 (2003) 387-398
63. Vennema H., Heijnen L., Zijderveld A., Horzinek M.C., and Spaan W.J. Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly. J Virol 64 1 (1990) 339-346
64. Corapi W.V., Darteil R.J., Audonnet J.C., and Chappuis G.E. Localization of antigenic sites of the S glycoprotein of feline infectious peritonitis virus involved in neutralization and antibody-dependent enhancement. J Virol 69 5 (1995) 2858-2862
65. Corapi W.V., Olsen C.W., and Scott F.W. Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J Virol 66 11 (1992) 6695-6705
66. Olsen C.W. A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet Microbiol 36 1-2 (1993) 1-37
67. Murphy B.R., Sotnikov A.V., Lawrence L.A., Banks S.M., and Prince G.A. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8 5 (1990) 497-502
68. Connors M., Collins P.L., Firestone C.Y., et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia-RSV recombinants or RSV. Vaccine 10 7 (1992) 475-484
69. Kakuk T.J., Soike K., Brideau R.J., et al. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J. Infect Dis 167 3 (1993) 553-561
70. Sullivan N.J. Antibody-mediated enhancement of viral disease. Curr Top Microbiol Immunol 260 (2001) 145-169
71. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 60 (2003) 421-467
72. Yang Z.Y., Werner H.C., Kong W.P., et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA 102 3 (2005) 797-801
73. Li L., Wo J., Shao J., et al. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. J Clin Virol 28 3 (2003) 239-244
74. Yilla M., Harcourt B.H., Hickman C.J., et al. SARS-coronavirus replication in human peripheral monocytes/macrophages. Virus Res 107 1 (2005) 93-101
75. World Health Organization. Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004). Geneva. World Health Organization. WHO Technical Report Series 2006; http://www.who.int/biologicals/ECBS55%20summary,%20November%202004.pdf, in press.
76. Ferguson M., Sands D., Lelie N., and Hepatitis. A immunoglobulin: an international collaborative study to establish the second international standard. Biologicals 28 4 (2000) 233-240
77. Forsey T., Heath A.B., and Minor P.D. The 1st International Standard for anti-measles serum. Biologicals 19 3 (1991) 237-241
78. Lyng J. Calibration of a replacement preparation for the International Standard for Rabies Immunoglobulin. Biologicals 22 3 (1994) 249-255
79. Ferguson M., and Heath A. Report of a collaborative study to calibrate the Second International Standard for parvovirus B19 antibody. Biologicals 32 4 (2004) 207-212
80. Gotch F., Holmes H., and Imami N. The importance of standardisation of laboratory evaluations in HIV vaccine trials. Microbes Infect 7 14 (2005) 1424-1432
81. Centre for AIDS reagents. National Institute for Biological Standards and Control (NIBSC). http://www.nibsc.ac.uk/spotlight/aids.html . (last accessed 25 April 2006).
82. Biodefense and Emerging Infections Research Resources Repository (BEI Resources). http://www.beiresources.org/ (last accessed 25 April 2006).
83. World Health Organization. Laboratory Biosafety Manual. 2nd ed. (revised ed.) (2003), World Health Organization, Geneva
84. WHO biosafety guidelines for handling of SARS specimens. http://www.who.int/csr/sars/biosafety2003_04_25/en/
85. Marshall E., and Enserink M.M. Caution urged on SARS vaccines. Science 303 5660 (2004) 944-946